Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives $48.00 Average PT from Brokerages

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $48.00.

Several brokerages have issued reports on COAG. HC Wainwright lifted their target price on shares of Hemab Therapeutics from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Jefferies Financial Group boosted their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Wedbush reaffirmed an “outperform” rating and issued a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a research report on Monday, July 13th. Evercore started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th.

Hemab Therapeutics Stock Performance

NASDAQ COAG opened at $49.23 on Friday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $52.15. The business has a fifty day moving average of $31.57. The stock has a market capitalization of $2.30 billion and a PE ratio of -2.05.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were purchased at an average price of $18.00 per share, with a total value of $48,150,000.00. Following the acquisition, the director directly owned 6,149,096 shares in the company, valued at $110,683,728. The trade was a 77.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders bought 2,970,541 shares of company stock valued at $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.